Walleye Capital
NVS icon

Walleye Capital’s Novartis NVS Stock Holding History

Walleye Capital’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.1M Buy
144,800
+17,900
+14% +$2.74M 0.09% 161
2025
Q4 		$17.5M Buy
126,900
+96,500
+317% +$12.6M 0.05% 350
2025
Q3 		$3.9M Sell
30,400
-6,400
-17% -$781K 0.01% 1087
2025
Q2 		$4.45M Buy
36,800
+31,600
+608% +$3.56M 0.02% 942
2025
Q1 		$580K Sell
5,200
-37,700
-88% -$4.01M ﹤0.01% 2429
2024
Q4 		$4.17M Sell
42,900
-41,500
-49% -$4.43M 0.01% 1204
2024
Q3 		$9.71M Sell
84,400
-10,400
-11% -$1.18M 0.02% 709
2024
Q2 		$10.1M Buy
94,800
+22,000
+30% +$2.21M 0.02% 749
2024
Q1 		$7.04M Buy
72,800
+5,300
+8% +$543K 0.01% 1063
2023
Q4 		$6.82M Sell
67,500
-6,600
-9% -$637K 0.01% 903
2023
Q3 		$7.55M Buy
74,100
+41,800
+129% +$4.24M 0.02% 746
2023
Q2 		$3.26M Buy
32,300
+25,600
+382% +$2.56M 0.01% 997
2023
Q1 		$616K Buy
+6,700
New +$585K 0.01% 1536

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Walleye Capital's NVS Position: Q1 2026 in Review

Walleye Capital increased its Novartis (NVS) stake by 1,373,300% in Q1 2026, buying an estimated $2.11M and bringing the position to 13,734 shares worth $2.1M. The position accounts for 0.01% of the portfolio, ranked #1426.

Walleye Capital first reported a position in NVS in Q3 2018 and has held it in 10 quarters since. The position peaked at $3.37M in Q3 2024. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Walleye Capital held 13,734 shares of Novartis worth $2.1M as of Q1 2026.
  • Walleye Capital bought 13,733 Novartis shares in Q1 2026, an estimated $2.11M.
  • Novartis made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1426 holding.
  • Walleye Capital first reported a position in Novartis in Q3 2018 and has held it in 10 quarters since.
  • Walleye Capital's Novartis position peaked at $3.37M in Q3 2024.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.